Rhythm Pharmaceuticals Expects to Dose First Phase III Patients in January

Your call?🐂 Bullish🐻 Bearish

The company committed $350 million to a royalty buy-down. CEO David Meeker cited $92 million in third-quarter revenue and called the U.S. launch an “excellent start.”